(Q46967376)

English

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma

scientific article published on 25 October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

1 reference

based on heuristic

inferred from title

author name string

Dimitrios Pectasides

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Nicolaos Xiros

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

George Papaxoinis

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Gerasimos Aravantinos

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Constantinos Sykiotis

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Erini Pectasides

6

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Amanda Psyrri

7

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Anna Koumarianou

8

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Asimina Gaglia

9

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Panayiotis Gouveris

10

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Theofanis Economopoulos

11

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

language of work or name

0 references

publication date

25 October 2007

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Gynecologic Oncology

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

108

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

47-52

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Management of platinum-sensitive recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Workshop: options for therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

CA125 response: can it replace the traditional response criteria in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Cisplatin/carboplatin cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.061

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.08.061

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17915300

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46967376&oldid=2140133967"